Last reviewed · How we verify
Single anti-platelet therapy
At a glance
| Generic name | Single anti-platelet therapy |
|---|---|
| Also known as | SAPT strategy |
| Sponsor | Lepu Medical Technology (Beijing) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (PHASE2)
- Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant (PHASE4)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- Dissection of the Superior Mesenteric Artery
- Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention (PHASE4)
- UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients (PHASE1)
- Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: